Literature DB >> 32714616

Screening for the Most Common Mutations of CFTR Gene among Egyptian Children with Difficult-to-Treat Asthma.

Mohammad Al-Haggar1, Engy Osman2, Abdel-Rahman Eid1, Tarek Barakat1, Samar El-Morsi3.   

Abstract

Cystic fibrosis (CF) is panethnic autosomal recessive disease that affects the exocrine glands of pancreas, lungs, and intestine. It is often misdiagnosed in developing countries as difficult-to-treat asthma. We enrolled 150 Egyptian families with one or more probands who were complaining of difficult-to-treat asthma, and 112 cases were studied extensively through history taking including pedigree construction and clinical examination. In addition, spirometry and computed tomography of the chest were done in selected cases. All cases were subjected to quantitative sweat chloride test and molecular screening for the three most common mutations of cystic fibrosis transconductance regulator ( CFTR ) gene ( ΔF508 , G542X , W1282X ) using amplification refractory mutation system (ARMS) technique. Probands of difficult-to-treat asthma comprised 66 males and 46 females; their age range was 1 to 14 years. Sixty-one probands (54.5%) were carriers of one or more of the studied mutations (36 cases and 25 carriers). Six carriers of single mutations had mild respiratory symptoms and negative sweat test. The most common allele was ΔF508 , 60 alleles in 56 individuals (4 were homozygous ΔF508 / ΔF508 ) followed by W1282X in 25 individuals and G542X in 12 individuals. Allele W1282X had an increased risk of recurrent chest infection and bronchiectasis. Moreover, cases with two mutations had more severe symptoms compared with those with a single mutation. CFTR mutations and CF-related syndromes are not rare as thought in Egypt, especially among the high-risk difficult-to-treat asthma. The readily available ARMS technique is recommended for ΔF508 and/or W1282X screening on priority basis among these children. © Thieme Medical Publishers.

Entities:  

Keywords:  CFTR; cystic fibrosis; difficult-to-treat asthma

Year:  2020        PMID: 32714616      PMCID: PMC7375845          DOI: 10.1055/s-0040-1701446

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  25 in total

1.  Cystic fibrosis: beyond the gene to therapy.

Authors:  E F Tizzano; M Buchwald
Journal:  J Pediatr       Date:  1992-03       Impact factor: 4.406

2.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis.

Authors:  Maggie L Naguib; Iris Schrijver; Phyllis Gardner; Lynn M Pique; Samiha S Doss; Mona A Abu Zekry; Mona Aziz; Samya Z Nasr
Journal:  J Cyst Fibros       Date:  2006-07-11       Impact factor: 5.482

Review 4.  Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.

Authors:  D Robinson; M Humbert; R Buhl; A A Cruz; H Inoue; S Korom; N A Hanania; P Nair
Journal:  Clin Exp Allergy       Date:  2017-02       Impact factor: 5.018

Review 5.  Asthma phenotypes in children and stratified pharmacological treatment regimens.

Authors:  Maria Iordanidou; Stelios Loukides; Emmanouil Paraskakis
Journal:  Expert Rev Clin Pharmacol       Date:  2016-12-20       Impact factor: 5.045

6.  Cystic fibrosis in bahrain incidence, phenotype, and outcome.

Authors:  F Al-Mahroos
Journal:  J Trop Pediatr       Date:  1998-02       Impact factor: 1.165

7.  Environmental risk factors for persistent asthma in Lucknow.

Authors:  Shally Awasthi; Sarika Gupta; Nutan Maurya; Priya Tripathi; Pratibha Dixit; Neeraj Sharma
Journal:  Indian J Pediatr       Date:  2012-06-14       Impact factor: 1.967

Review 8.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

9.  Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis.

Authors:  C Goubau; M Wilschanski; V Skalická; P Lebecque; K W Southern; I Sermet; A Munck; N Derichs; P G Middleton; L Hjelte; R Padoan; M Vasar; K De Boeck
Journal:  Thorax       Date:  2009-03-23       Impact factor: 9.139

Review 10.  Diagnosis of cystic fibrosis.

Authors:  Karen Z Voter; Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.